--News Direct--
Voyageur Pharmaceuticals CEO Brent Willis join's Proactive's Natalie Stoberman to share a significant licensing agreement with Rain Cage Carbon to develop nanocarbon-based contrast drugs for medical imaging.
Willis says the partnership aims to develop new contrast agents for the radiology drug market while also making Voyageur the first carbon-neutral pharmaceutical company in the industry.
He explains that Rain Cage Carbon's innovative technology allows Voyageur to extract carbon dioxide and other emissions, generating high-grade carbon for various applications. By leveraging this technology, Willis says Voyageur plans to create safer and more effective drugs using carbon 60 molecules.
Contact Details
Proactive Investors
+1 604-688-8158
na-editorial@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/voyageur-pharmaceuticals-partners-with-rain-cage-to-develop-nanocarbon-based-radiology-drugs-978401672
